Beverly Incledon
Director/Board Member chez PHARMATHER HOLDINGS LTD.
Profil
Beverly James Incledon is currently the Director & Chief Scientific Officer at Ironshore Pharmaceutical & Development, Inc. and an Independent Director at PharmaTher Holdings Ltd.
Previously, she held positions as the Director-Research & Development at Eli Lilly Canada, Inc. from 2006 to 2009, Vice President-Development at Trillium Therapeutics ULC, Vice President-Research & Development at Pacgen Life Science Corp.
from 2009 to 2010, and President at Concept 2 Clinic, Inc. from 2010 to 2014.
She also served as the Vice President-Research & Development at Revive Therapeutics Ltd.
Dr. Incledon obtained her undergraduate and doctorate degrees from the University of Guelph in 1998.
Postes actifs de Beverly Incledon
| Sociétés | Poste | Début |
|---|---|---|
| PHARMATHER HOLDINGS LTD. | Director/Board Member | 01/06/2020 |
Ironshore Pharmaceutical & Development, Inc.
 Ironshore Pharmaceutical & Development, Inc. BiotechnologyHealth Technology Part of Ironshore Therapeutics, Inc., Ironshore Pharmaceutical & Development, Inc. develops novel therapeutics using its proprietary controlled-release drug-delivery technology. The private company is based in Camana Bay, Cayman Islands. Our lead products are developed using a unique and beneficial delayed-release and extended-release delivery to a specifically targeted area. Ironshore is a fully Caymanian integrated pharmaceutical company with experience developing and commercializing first-in-class therapeutic products. JORNAY PM is a first-in-class product indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older. The company is committed to the development and commercialization of first-in-class treatment options to improve the lives of patients and caregivers. The CEO of the company is David Gordon MacLeod Lickrish. | Chief Tech/Sci/R&D Officer | 01/01/2014 |
Anciens postes connus de Beverly Incledon
| Sociétés | Poste | Fin |
|---|---|---|
Concept 2 Clinic, Inc.
 Concept 2 Clinic, Inc. Miscellaneous Commercial ServicesCommercial Services Concept 2 Clinic, Inc. operates as an executive research and development management company that specializes in pharmaceutical and biotechnology sectors. Its services include financial, opportunity assessment, pre-clinical and CMC. The company is headquartered in Markham, Canada. | President | 01/01/2014 |
| PACGEN LIFE SCIENCE CORPORATION | Chief Tech/Sci/R&D Officer | 01/01/2010 |
Eli Lilly Canada, Inc.
 Eli Lilly Canada, Inc. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Canada, Inc. is a healthcare leader that focuses on oncology, diabetes, autoimmunity, neurodegeneration, and pain. The private company is based in Scarborough, Canada. Established in 1938, the Canadian company collaborates with scientists to produce innovative medicines that make life better for people around the world. The company's mission is to discover and bring life-changing medicines to people who need them, improve the understanding and management of disease, and contribute to communities through philanthropy and volunteerism. | Corporate Officer/Principal | 01/04/2009 |
| REVIVE THERAPEUTICS LTD. | Chief Tech/Sci/R&D Officer | - |
| TRILLIUM THERAPEUTICS | Corporate Officer/Principal | - |
Formation de Beverly Incledon
| University of Guelph | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| REVIVE THERAPEUTICS LTD. | Health Technology |
| PHARMATHER HOLDINGS LTD. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
Eli Lilly Canada, Inc.
Eli Lilly Canada, Inc. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Canada, Inc. is a healthcare leader that focuses on oncology, diabetes, autoimmunity, neurodegeneration, and pain. The private company is based in Scarborough, Canada. Established in 1938, the Canadian company collaborates with scientists to produce innovative medicines that make life better for people around the world. The company's mission is to discover and bring life-changing medicines to people who need them, improve the understanding and management of disease, and contribute to communities through philanthropy and volunteerism. | Health Technology |
Pacgen Life Science Corp.
 Pacgen Life Science Corp. BiotechnologyHealth Technology Pacgen Life Science Corp. is a life science technology company, which engages in the development and commercialization of biomedical products and services. It specializes in the operation of global commercial platform to market and distribute consumer health products developed by small business enterprises. The company focuses on oral care and skin care commercial rights. Pacgen Life Science was founded by Fred Huang and Chung Yu Wang on April 23, 2004 and is headquartered in Vancouver, Canada. | Health Technology |
Concept 2 Clinic, Inc.
Concept 2 Clinic, Inc. Miscellaneous Commercial ServicesCommercial Services Concept 2 Clinic, Inc. operates as an executive research and development management company that specializes in pharmaceutical and biotechnology sectors. Its services include financial, opportunity assessment, pre-clinical and CMC. The company is headquartered in Markham, Canada. | Commercial Services |
Ironshore Pharmaceutical & Development, Inc.
Ironshore Pharmaceutical & Development, Inc. BiotechnologyHealth Technology Part of Ironshore Therapeutics, Inc., Ironshore Pharmaceutical & Development, Inc. develops novel therapeutics using its proprietary controlled-release drug-delivery technology. The private company is based in Camana Bay, Cayman Islands. Our lead products are developed using a unique and beneficial delayed-release and extended-release delivery to a specifically targeted area. Ironshore is a fully Caymanian integrated pharmaceutical company with experience developing and commercializing first-in-class therapeutic products. JORNAY PM is a first-in-class product indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older. The company is committed to the development and commercialization of first-in-class treatment options to improve the lives of patients and caregivers. The CEO of the company is David Gordon MacLeod Lickrish. | Health Technology |
